PMID- 34260091
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 47
IP  - 1
DP  - 2022 Jan
TI  - Acquired perforating dermatoses show increased levels of cutaneous advanced 
      glycation end-products.
PG  - 80-85
LID - 10.1111/ced.14851 [doi]
AB  - BACKGROUND: Acquired perforating dermatoses (APDs) are characterized by 
      transepidermal elimination of skin materials. Altered glycation of dermal 
      components may be involved in pathogenesis. AIM: To assess whether patients 
      affected by APDs have increased levels of cutaneous advanced glycation 
      end-products (AGEs). METHODS: A cross-sectional controlled study involving a 
      total of 109 patients was conducted, enrolling 29 patients consecutively 
      diagnosed with primary APDs [reactive perforating collagenosis (RPC), elastosis 
      perforans serpiginosa (EPS), perforating folliculitis (PF) and Kyrle disease 
      (KD)], 40 age- and sex-matched healthy controls (HCs) and 40 patients with mild 
      atopic dermatitis (AD). The levels of cutaneous AGEs were measured using a 
      validated fluorescence technique. RESULTS: The median skin autofluorescence value 
      in patients with APDs was significantly higher [2.7 arbitrary units (AU), 
      interquartile range (IQR) 1.9-3.9 AU] compared with HCs (1.8 AU, IQR 1.6-2.3 AU; 
      P < 0.001) and patients with AD (2.1 AU, IQR 1.9-2.3 AU; P = 0.01). Median values 
      were 3.5 AU (IQR 2.7-4.6 AU) for RPC, 1.83.5 AU (1.4-2.4 AU) for EPS, 3.1 AU 
      (2.4-4.4 AU) for PF and 2.6 AU (2.3-3.1 AU) for KD. CONCLUSIONS: Our results may 
      suggest a possible physiopathological role of AGEs in the transepidermal 
      elimination mechanisms involved in certain APDs.
CI  - (c) 2021 British Association of Dermatologists.
FAU - Bellinato, F
AU  - Bellinato F
AUID- ORCID: 0000-0002-6163-6921
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Maurelli, M
AU  - Maurelli M
AUID- ORCID: 0000-0001-7492-8010
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Gisondi, P
AU  - Gisondi P
AUID- ORCID: 0000-0002-1777-9001
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Girolomoni, G
AU  - Girolomoni G
AUID- ORCID: 0000-0001-8548-0493
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210827
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Glycation End Products, Advanced)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glycation End Products, Advanced/*analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Skin/*chemistry
MH  - Skin Diseases/*pathology
MH  - Young Adult
EDAT- 2021/07/15 06:00
MHDA- 2022/03/04 06:00
CRDT- 2021/07/14 12:37
PHST- 2021/07/09 00:00 [accepted]
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/07/14 12:37 [entrez]
AID - 10.1111/ced.14851 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2022 Jan;47(1):80-85. doi: 10.1111/ced.14851. Epub 2021 Aug 
      27.